Materias dentro de su búsqueda.
Materias dentro de su búsqueda.
Historia
24
Películas cinematográficas
16
Música popular
13
Novela estadounidense
12
Jazz
10
Música para órgano
7
Crítica e interpretación
6
Música rock
6
Correspondencia
5
Comedy films
4
Condiciones sociales
4
Diarios íntimos
4
Estados Unidos
4
Música
4
Música vocal (Jazz)
4
Novelistas ingleses
4
Arte
3
Aspectos sociales
3
Bailarines
3
Blues (Música)
3
Christmas music
3
Foreign films
3
Historia y crítica
3
Libros falsos
3
Literatura estadounidense
3
Motetes
3
Música de jazz
3
Operas
3
Songs (High voice) with piano
3
Songs (Medium voice) with piano
3
-
5921por Barroso-Sousa, Romualdo, Tarantino, Paolo, Tayob, Nabihah, Dang, Chau, Yardley, Denise A., Isakoff, Steven J., Valero, Vicente, Faggen, Meredith, Mulvey, Therese, Bose, Ron, Hu, Jiani, Weckstein, Douglas, Wolff, Antonio C., Reeder-Hayes, Katherine, Rugo, Hope S., Ramaswamy, Bhuvaneswari, Zuckerman, Dan, Hart, Lowell, Gadi, Vijayakrishna K., Constantine, Michael, Cheng, Kit, Briccetti, Frederick, Schneider, Bryan, Garrett, Audrey Merrill, Marcom, Kelly, Albain, Kathy, DeFusco, Patricia, Tung, Nadine, Ardman, Blair, Nanda, Rita, Jankowitz, Rachel C., Rimawi, Mothaffar, Abramson, Vandana, Pohlmann, Paula R., Van Poznak, Catherine, Forero-Torres, Andres, Liu, Minetta, Ruddy, Kathryn J., Zheng, Yue, Rosenberg, Shoshana M., Gelber, Richard D., Trippa, Lorenzo, Barry, William, DeMeo, Michelle, Burstein, Harold, Partridge, Ann, Winer, Eric P., Krop, Ian, Tolaney, Sara M.“…The excellent outcomes seen in patients treated with adjuvant trastuzumab emtansine (T-DM1) in the ATEMPT trial and the favorable toxicity profile associated with this agent make T-DM1 a potential therapeutic option for select patients with stage I HER2-positive breast cancer. Moreover, T-DM1 is an established adjuvant treatment for patients with HER2-positive breast cancer with the residual invasive disease after neoadjuvant therapy. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5922por Li, Jian, Luo, Hui, Liu, Ying-Ying, Chen, Li-Xin, Zhu, Mei-Qin, Deng, Quan-Tong, Zhu, Dong-Mei, Wang, Zi-Mo, Xu, Jin-Feng“…METHODS: Fifty patients with HER-2 positive breast cancer who planned to receive trastuzumab and pertuzumab therapy for more than four cycles were enrolled in this study, and blood samples were collected. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5923por Liu, Yu, Wang, Ying, Wang, Yuxiang, Xie, Yu, Cui, Yanfen, Feng, Senwen, Yao, Mengxia, Qiu, Bingjiang, Shen, Wenqian, Chen, Dong, Du, Guoqing, Chen, Xin, Liu, Zaiyi, Li, Zhenhui, Yang, Xiaotang, Liang, Changhong, Wu, Lei“…BACKGROUND: Early prediction of treatment response to neoadjuvant chemotherapy (NACT) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer can facilitate timely adjustment of treatment regimens. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5924por Reinisch, Mattea, Untch, Michael, Mahlberg, Rolf, Reimer, Toralf, Hitschold, Thomas, Marmé, Frederik, Aydogdu, Mustafa, Schmatloch, Sabine, Lück, Hans-Joachim, Schmidt, Marcus, Ladda, Ekkehart, Sinn, Bruno Valentin, Klare, Peter, Janni, Wolfgang, Jackisch, Christian, Denkert, Carsten, Seiler, Sabine, Göhler, Thomas, Michel, Laura, Burchardi, Nicole, Stickeler, Elmar, Rey, Julia, Klutinus, Nicole, Möbus, Volker, Loibl, Sibylle“…BACKGROUND: Trastuzumab given intravenously in combination with chemotherapy is standard of care for patients with early HER2-positive breast cancer (BC). Different randomised studies have shown equivalent efficacy of a subcutaneous injection into the thigh compared to the intravenous formulation. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5925por Crager, Michael, Wijayawardana, Sameera R., Gruver, Aaron M., Blacklock, Andrea, Russell, Christy, Baehner, Frederick L., Sapunar, Francisco“…The Oncotype Dx Breast Recurrence Score® assay has been validated in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) invasive breast cancer (IBC) to predict chemotherapy benefit and distant recurrence risk, regardless of nodal status. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5926por Pohlmann, Paula R., Graham, Deena, Wu, Tianmin, Ottaviano, Yvonne, Mohebtash, Mahsa, Kurian, Shweta, McNamara, Donna, Lynce, Filipa, Warren, Robert, Dilawari, Asma, Rao, Suman, Mainor, Candace, Swanson, Nicole, Tan, Ming, Isaacs, Claudine, Swain, Sandra M.“…PURPOSE: To assess whether crofelemer would prevent chemotherapy-induced diarrhea (CID) diarrhea in patients with HER2-positive, any-stage breast cancer receiving trastuzumab (H), pertuzumab (P), and a taxane (T; docetaxel or paclitaxel), with/without carboplatin (C; always combined with docetaxel rather than paclitaxel). …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5927“…BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is the most prominent therapeutic target for advanced gastric (G)/GEJ cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5928por Allahyari, Abolghasem, Ehsanpour, Ali, Najafi, Behrouz, Ansarinejad, Nafseh, Mehrzad, Valiollah, Kalantari, Behjat, Raafat, Jahangir, Ghadiany, Mojtaba, Shahi, Farhad, Gharib, Behrooz, Moazed, Vahid, Khosravi, Adnan, Mirpour, Mir Hossein, Salari, Sina, Mortazavizadeh, Seyedmohammadreza, Nekoyi, Amirabbas, Khani, Mohsen, Sadeghi, Alireza, Gharib, Sirus, Bary, Alireza, Mirzania, Mehrzad, Haghighat, Shirin, Razavi, Seyed Mohsen, Emami, Seyed Amir Hossein, Hosseinzadeh, Mehran, Mirbolouk, Mahdi, Sadighi, Sanambar, Shahrasbi, Abdolali, Esfahani, Ali, Gity, Masoumeh, Anjidani, Nassim, Kaf, Hamidreza, Najaf, SafaEnlace del recurso
Publicado 2022
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5929por Zhou, Meirong, Wang, Shouman, Wan, Nengbin, Yuan, Songlin, Hu, Xiongqiang, Zhou, Wei, Qing, Bohua, Liu, Mingwen, Sun, Weihua, Fan, Peizhi, Wang, Jianguo, Cao, Hong, Xu, Haifan, Dai, Bin, Tang, Peizhi, Qian, Liyuan, Zhao, Xi, Xiao, Jun, Zhou, Huaiying, Hu, Jinhui, Ding, Li, Tripodi, Domenico, Zdenkowski, Nicholas, O’Keefe, Thomas J., Sanchez, Alejandro Martin, Chen, Li, Zhang, Ping, Xu, Feng“…BACKGROUND: Pertuzumab plus trastuzumab combined with chemotherapy has become a standard neoadjuvant therapy option for patients with high-risk human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). There is still not enough evidence for the efficacy and safety of neoadjuvant pertuzumab and trastuzumab plus chemotherapy in HER2-positive BC patients in China, both in clinical trials and real-world settings. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
5930
-
5931
-
5932
-
5933
-
5934
-
5935
-
5936
-
5937
-
5938
-
5939
-
5940